These growth factors enhance the expression and phosphorylation of annexin A2 (ANXA2), which endorse the resistance to the EGFR-TKI (gefitinib) in NSCLC (HCC827 and PC9) cells-harboring EGFR activating mutations [Figure 2A]. The gene discussed is ANXA2; the disease is non-small cell lung carcinoma.